CAS: 60-92-4; (4Ar,6R,7R,7As)-6-(6-Amino-9H-Purin-9-yl)-2,7-Dihydroxytetrahydro-4H-Furo[3,2-D][1,3,2]Dioxaphosphinine 2-Oxide

相似化合物

37839-81-9 41941-56-4 23583-48-4

上下游产品

CAS号34051-17-7 (2R,3R,4S,5R)-2... | CAS号58-61-7 腺苷 | CAS号56-65-5 5'-三磷酸腺苷 | CAS号61-19-8 腺苷酸 | CAS号339291-47-3 equatorial-[7-(... | CAS号339291-37-1 axial-[7-(dieth... | CAS号339291-49-5 [7-(carboxymeth... | CAS号339291-40-6 [7-(carboxymeth... | CAS号339291-51-9 cyclic adenosin... | CAS号58-61-7 腺苷 | CAS号84-21-9 腺苷 3'-单磷酸 | CAS号61-19-8 腺苷酸 | CAS号23583-48-4 8-溴腺苷-3',5'-环单磷酸 | CAS号73-24-5 腺嘌呤 | CAS号293304-89-9 D-ribo-3,4,5-Tr... | CAS号81158-47-6 D-ribo-2,4,5-Tr... | CAS号56-65-5 5'-三磷酸腺苷 | CAS号3545-76-4 肌苷3',5'-环一磷酸 | CAS号32115-08-5 6-bn-camp sodiu...

[[(2R,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-Dihydroxyoxolan-2-Yl]Methoxy-(Trichloromethyl)Phosphoryl]Oxyazanium 反应生成 腺苷环磷酸酯
参考文献:Marumoto,Ryudzi;Nisimura,Tatsuo;Xondze,Mikio
标题:Marumoto,Ryudzi;Nisimura,Tatsuo;Xondze,Mikio

专利信息

专利号:US-6168931-B1
优先权日:1999-03-17
标题 :Enhanced in vitro synthesis of biological macromolecules using a novel ATP regeneration system
发明人：SWARTZ JAMES R; KIM DONG-MYUNG
权利人:UNIV LELAND STANFORD JUNIOR
摘要:Compositions and methods are provided for the enhanced in vitro synthesis of biological molecules where ATP is required for synthesis. Of particular interest is the synthesis of polymers, e.g. nucleic acids, polypeptides, and complex carbohydrates. A homeostatic system is used for production of ATP, where the required high energy phosphate bonds are generated in situ, e.g. through coupling with an oxidation reaction. The homeostatic energy source will typically lack high energy phosphate bonds itself, and will therefore utilize free phosphate in the reaction mix during generation of ATP. Since inorganic phosphate can be an inhibitory by-product of synthesis, the period of time when synthesis is maintained in vitro can be extended. The homeostatic energy source is provided in combination with an enzyme that catalyzes the creation of high energy phosphate bonds and with an enzyme that can use that high energy phosphate bond to regenerate ATP.

专利号:US-2005153390-A1
优先权日:2002-05-14
标 题 :Lyophilized preparation for synthesis of cell-free protein
发明人：ENDO YAETA; OGASAWARA TOMIO
权利人:CELLFREE SCIENCES CO LTD
摘要:Lyophilized preparations from cell extract for use in cell-free protein, which exhibit an activity for protein synthesis being in no way inferior to that exhibited in low-temperature storage; and a method of utilizing the same. In particular, preparations are formed by performing lyophilization after reducing the concentration of deliquescent substances in a solution containing cell extract for synthesis of cell-free protein to a level not detrimental to the quality of preparations after lyophilization.

专利号:US-6548276-B2
优先权日:2000-09-06
标题:Enhanced in vitro synthesis of active proteins containing disulfide bonds
发明人：SWARTZ JAMES ROBERT; KIM DONG-MYUNG
权利人:UNIV LELAND STANFORD JUNIOR
摘要:Compositions and methods are provided for the enhanced in vitro synthesis of polypeptides containing disulfide bonds. In order to improve the performance of in vitro protein synthesis reactions, pre-treatment and redox buffering of the reaction mix is performed in order to optimize the redox potential. Exogenous enzymes that enhance protein folding and disulfide bond formation may also be added to the reaction.

专利号:US-2012208232-A1
优先权日:2009-07-15
标 题:Cell-Free Synthesis of Active Reprogramming Transcription Factors
发明人：YANG WILLIAM; PATEL KEDAR; GHEBREMARIAM YOHANNES T; LEE JI EUN; WONG HANN-CHUNG; COOKE JOHN P; SWARTZ JAMES ROBERT
权利人:YANG WILLIAM; PATEL KEDAR; GHEBREMARIAM YOHANNES T; LEE JI EUN; WONG HANN-CHUNG; COOKE JOHN P; SWARTZ JAMES ROBERT
摘要:Compositions and methods are provided for the cell-free synthesis of active reprogramming factor polypeptides. The reprogramming factors may be synthesized as fusion proteins comprising a permeant domain, such as polyarginme. The cell free-synthesis may be conducted at about 25 C in a bacterial cell extract from genetically alterd cells having decreased endogenous protease activity Further, the proteins may comprise a fusion partner which enhances solubility and may be refolded on a column.

专利号:US-6994986-B2
优先权日:1999-03-17
标 题:In vitro synthesis of polypeptides by optimizing amino acid metabolism
发明人：SWARTZ JAMES ROBERT; KIM DONG-MYUNG
权利人:UNIV LELAND STANFORD JUNIOR
摘要:Compositions and methods are provided for the enhanced in vitro synthesis of polypeptides. In order to improve the performance of in vitro protein synthesis reactions, metabolic inhibitors, or manipulation of a source organism, is used to diminish or avoid the action of enzymes responsible for undesirable amino acids production or depletion. A homeostatic system may be used for production of ATP, where the required high energy phosphate bonds are generated in situ, e.g. through coupling with an oxidation reaction. The homeostatic energy source will typically lack high energy phosphate bonds itself, and will therefore utilize free phosphate in the reaction mix during generation of ATP. The homeostatic energy source is provided in combination with an enzyme that catalyzes the creation of high energy phosphate bonds and with an enzyme that can use that high energy phosphate bond to regenerate ATP.

专利号:US-2023398215-A1
优先权日:2020-10-28
标 题:Genetically engineered antigen-specific natural killer cells for in situ synthesis of proteins
发明人：BHATNAGAR PARIJAT
权利人:STANFORD RES INST INT
摘要:An example genetically engineered natural killer (NK) cell comprises an exogenous polynucleotide sequence that includes a receptor element, an actuator element, and an effector element. The receptor element encodes a chimeric antigen receptor (CAR) comprising an extracellular antigen binding domain operably linked to a transmembrane domain, and an intracellular signaling domain, wherein the extracellular antigen binding domain recognizes a surface antigen of a target cell. The actuator element encodes a transcription factor binding site that upregulates synthesis of an effector protein. The effector element encodes the effector protein operably linked to a signal peptide, wherein, in response to the antigen binding domain of the CAR binding to the antigen of the target cell, the engineered NK cell is configured to activate and, to synthesize and secrete the effector protein.